Pozzan et al., 2014 - Google Patents
Diagnostic and prognostic role of SCCA‐IgM serum levels in hepatocellular carcinoma (HCC)Pozzan et al., 2014
View PDF- Document ID
- 7898836472472389442
- Author
- Pozzan C
- Cardin R
- Piciocchi M
- Cazzagon N
- Maddalo G
- Vanin V
- Giacomin A
- Pontisso P
- Cillo U
- Farinati F
- Publication year
- Publication venue
- Journal of gastroenterology and hepatology
External Links
Snippet
Abstract Background and Aim The serpin squamous cell carcinoma antigen complexed with IgM (SCCA‐IgM) has been reported as a promising serological marker for hepatocellular carcinoma (HCC). We aimed to further evaluate SCCA‐IgM diagnostic accuracy and to …
- 206010073071 Hepatocellular carcinoma 0 title abstract description 86
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F9/00—Arrangements for programme control, e.g. control unit
- G06F9/06—Arrangements for programme control, e.g. control unit using stored programme, i.e. using internal store of processing equipment to receive and retain programme
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pozzan et al. | Diagnostic and prognostic role of SCCA‐IgM serum levels in hepatocellular carcinoma (HCC) | |
| Sun et al. | Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: neutrophil‐lymphocyte ratio and platelet‐lymphocyte ratio | |
| Salami et al. | Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer | |
| Sengupta et al. | Biomarker development for hepatocellular carcinoma early detection: current and future perspectives | |
| Eggener et al. | Gleason 6 prostate cancer: translating biology into population health | |
| He et al. | CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis | |
| Maertens et al. | Prospective clinical evaluation of lower cut‐offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients | |
| Cai et al. | EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies | |
| Sokoll et al. | [-2] proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study | |
| Marrero | Screening tests for hepatocellular carcinoma | |
| Shaheen et al. | The value of serum midkine level in diagnosis of hepatocellular carcinoma | |
| Iseda et al. | Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma | |
| Welty et al. | Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer | |
| Trenti et al. | Diagnostic predictive value of the Bladder EpiCheck test in the follow‐up of patients with non–muscle‐invasive bladder cancer | |
| Reichl et al. | Multicenter analysis of soluble A xl reveals diagnostic value for very early stage hepatocellular carcinoma | |
| Chandarana et al. | Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer | |
| Tsang et al. | αB‐crystallin is a useful marker for triple negative and basal breast cancers | |
| Liu et al. | Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems | |
| Kudahetti et al. | p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer | |
| Gaya et al. | ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer | |
| Lotan et al. | Optimal trial design for studying urinary markers in bladder cancer: a collaborative review | |
| Kunizaki et al. | Clinical value of serum p53 antibody in the diagnosis and prognosis of colorectal cancer | |
| Li et al. | Thioredoxin reductase: a novel, independent prognostic marker in patients with hepatocellular carcinoma | |
| Ecke et al. | Preliminary results of a multicentre study of the UBC rapid test for detection of urinary bladder cancer | |
| Zhu et al. | A new laboratory-based algorithm to predict microvascular invasion and survival in patients with hepatocellular carcinoma |